Idorsia Ltd
SIX:IDIA
Idorsia Ltd
Stock-Based Compensation
Idorsia Ltd
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Stock-Based Compensation
CHf5.9m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Stock-Based Compensation
$72.5m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
35%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Stock-Based Compensation
CHf5.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-6%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Stock-Based Compensation
CHf949.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Stock-Based Compensation
CHf297k
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Stock-Based Compensation?
Stock-Based Compensation
5.9m
CHF
Based on the financial report for Dec 31, 2025, Idorsia Ltd's Stock-Based Compensation amounts to 5.9m CHF.
What is Idorsia Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-21%
Over the last year, the Stock-Based Compensation growth was -48%. The average annual Stock-Based Compensation growth rates for Idorsia Ltd have been -39% over the past three years , -21% over the past five years .
